Health Canada advisory: SGLT2 inhibitors and prolonged or incident diabetic ketoacidosisTake note of this Health Canada advisory as part of our October drug news update. NEW DRUG: Wyost approved for two cancer-related indicationsGet the info you need on this new product, part of our drug news roundup for October. NEW DRUG: Jubbonti approved for several indications Get the info you need on this new product, part of our drug news roundup for October. NEW DRUG: Cabtreo: topical triple-therapy for acne Get the info you need on this new product, part of our drug news roundup for October. NEW DRUG: Asparlas for acute lymphoblastic leukemia Get the info you need on this new product, part of our drug news roundup for October. Safety of simultaneous administration of adjuvanted zoster vaccine and adjuvanted flu vaccine Study compares the safety and reactogenicity of simultaneous doses of Shingrix and Fluad versus simultaneous doses of Shingrix and Fluzone High-Dose Quadrivalent. Lower risk of abandoning treatment for opioid use disorder with methadone Study looked at data from a decade of treatment of opioid use disorder in British Columbia. Non-hormonal drugs show promise for moderate to severe menopause symptoms Treatments that tackle vasomotor symptoms like hot flushes head-on, without hormones, are increasingly coming onto the market. Taking a vasodilator in film form allows treatment erectile dysfunction to be more discreet Viagra in orodispersible film form is now available in Canada. Cabtreo gel is the first topical triple-therapy combination product for acne The three ingredients—clindamycin, adapalene and benzoyl peroxide—have complementary mechanisms of action targeting the pathology of acne vulgaris. First Previous 8 9 10 11 12 Next Last
